 | • レポートコード：MRC2-11QY09037 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は再発急性骨髄性白血病治療薬のグローバル市場について調査・分析したレポートです。種類別（aNKプログラム、AT-9283、BI-836858、ビニメチニブ、BL-8040、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別再発急性骨髄性白血病治療薬の競争状況、市場シェア ・世界の再発急性骨髄性白血病治療薬市場：種類別市場規模 2015年-2020年（aNKプログラム、AT-9283、BI-836858、ビニメチニブ、BL-8040、その他） ・世界の再発急性骨髄性白血病治療薬市場：種類別市場規模予測 2021年-2026年（aNKプログラム、AT-9283、BI-836858、ビニメチニブ、BL-8040、その他） ・世界の再発急性骨髄性白血病治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の再発急性骨髄性白血病治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の再発急性骨髄性白血病治療薬市場分析：米国、カナダ ・ヨーロッパの再発急性骨髄性白血病治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの再発急性骨髄性白血病治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の再発急性骨髄性白血病治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの再発急性骨髄性白血病治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：4SC AG、AbbVie Inc.、Actinium Pharmaceuticals, Inc.、Agios Pharmaceuticals, Inc.、Amgen Inc.、Arog Pharmaceuticals, Inc.、Array BioPharma Inc.、Astellas Pharma Inc.、Astex Pharmaceuticals, Inc.、AstraZeneca Plc、AVEO Pharmaceuticals, Inc.、BioLineRx, Ltd.、Boehringer Ingelheim GmbH、Boston Biomedical, Inc.、Bristol-Myers Squibb Company、Calithera Biosciences, Inc.、Celgene Corporation、Cornerstone Pharmaceuticals, Inc.、CTI BioPharma Corp. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Relapsed Acute Myeloid Leukemia Drug Market
The global Relapsed Acute Myeloid Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Relapsed Acute Myeloid Leukemia Drug Scope and Market Size
Relapsed Acute Myeloid Leukemia Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Relapsed Acute Myeloid Leukemia Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Relapsed Acute Myeloid Leukemia Drug market is segmented into
aNK Program
AT-9283
BI-836858
binimetinib
BL-8040
Others
Segment by Application, the Relapsed Acute Myeloid Leukemia Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Relapsed Acute Myeloid Leukemia Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Relapsed Acute Myeloid Leukemia Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
Relapsed Acute Myeloid Leukemia Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Relapsed Acute Myeloid Leukemia Drug business, the date to enter into the Relapsed Acute Myeloid Leukemia Drug market, Relapsed Acute Myeloid Leukemia Drug product introduction, recent developments, etc.
The major vendors covered:
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
1 Study Coverage
1.1 Relapsed Acute Myeloid Leukemia Drug Product Introduction
1.2 Market Segments
1.3 Key Relapsed Acute Myeloid Leukemia Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type
1.4.2 aNK Program
1.4.3 AT-9283
1.4.4 BI-836858
1.4.5 binimetinib
1.4.6 BL-8040
1.4.7 Others
1.5 Market by Application
1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size, Estimates and Forecasts
2.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue 2015-2026
2.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales 2015-2026
2.2 Global Relapsed Acute Myeloid Leukemia Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Relapsed Acute Myeloid Leukemia Drug Competitor Landscape by Players
3.1 Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
3.1.1 Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (2015-2020)
3.1.2 Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
3.2.1 Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2015-2020)
3.2.2 Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Relapsed Acute Myeloid Leukemia Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Relapsed Acute Myeloid Leukemia Drug Revenue in 2019
3.2.5 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Relapsed Acute Myeloid Leukemia Drug Price by Manufacturers
3.4 Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Product Types
3.4.1 Relapsed Acute Myeloid Leukemia Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
3.4.3 Date of International Manufacturers Enter into Relapsed Acute Myeloid Leukemia Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Type (2015-2020)
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2015-2020)
4.1.3 Relapsed Acute Myeloid Leukemia Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Type (2021-2026)
4.2.3 Relapsed Acute Myeloid Leukemia Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Application (2015-2020)
5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020)
5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2015-2020)
5.1.3 Relapsed Acute Myeloid Leukemia Drug Price by Application (2015-2020)
5.2 Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Relapsed Acute Myeloid Leukemia Drug by Country
6.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country
6.1.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Type
6.3 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Relapsed Acute Myeloid Leukemia Drug by Country
7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country
7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Type
7.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug by Region
8.1.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region
8.1.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Type
8.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Relapsed Acute Myeloid Leukemia Drug by Country
9.1.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country
9.1.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Type
9.3 Central & South America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug by Country
10.1.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country
10.1.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Type
10.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Application
11 Company Profiles
11.1 4SC AG
11.1.1 4SC AG Corporation Information
11.1.2 4SC AG Description and Business Overview
11.1.3 4SC AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Products Offered
11.1.5 4SC AG Related Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Corporation Information
11.2.2 AbbVie Inc. Description and Business Overview
11.2.3 AbbVie Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.2.5 AbbVie Inc. Related Developments
11.3 Actinium Pharmaceuticals, Inc.
11.3.1 Actinium Pharmaceuticals, Inc. Corporation Information
11.3.2 Actinium Pharmaceuticals, Inc. Description and Business Overview
11.3.3 Actinium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.3.5 Actinium Pharmaceuticals, Inc. Related Developments
11.4 Agios Pharmaceuticals, Inc.
11.4.1 Agios Pharmaceuticals, Inc. Corporation Information
11.4.2 Agios Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Agios Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.4.5 Agios Pharmaceuticals, Inc. Related Developments
11.5 Amgen Inc.
11.5.1 Amgen Inc. Corporation Information
11.5.2 Amgen Inc. Description and Business Overview
11.5.3 Amgen Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.5.5 Amgen Inc. Related Developments
11.6 Arog Pharmaceuticals, Inc.
11.6.1 Arog Pharmaceuticals, Inc. Corporation Information
11.6.2 Arog Pharmaceuticals, Inc. Description and Business Overview
11.6.3 Arog Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.6.5 Arog Pharmaceuticals, Inc. Related Developments
11.7 Array BioPharma Inc.
11.7.1 Array BioPharma Inc. Corporation Information
11.7.2 Array BioPharma Inc. Description and Business Overview
11.7.3 Array BioPharma Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.7.5 Array BioPharma Inc. Related Developments
11.8 Astellas Pharma Inc.
11.8.1 Astellas Pharma Inc. Corporation Information
11.8.2 Astellas Pharma Inc. Description and Business Overview
11.8.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.8.5 Astellas Pharma Inc. Related Developments
11.9 Astex Pharmaceuticals, Inc.
11.9.1 Astex Pharmaceuticals, Inc. Corporation Information
11.9.2 Astex Pharmaceuticals, Inc. Description and Business Overview
11.9.3 Astex Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
11.9.5 Astex Pharmaceuticals, Inc. Related Developments
11.10 AstraZeneca Plc
11.10.1 AstraZeneca Plc Corporation Information
11.10.2 AstraZeneca Plc Description and Business Overview
11.10.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Products Offered
11.10.5 AstraZeneca Plc Related Developments
11.1 4SC AG
11.1.1 4SC AG Corporation Information
11.1.2 4SC AG Description and Business Overview
11.1.3 4SC AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Products Offered
11.1.5 4SC AG Related Developments
11.12 BioLineRx, Ltd.
11.12.1 BioLineRx, Ltd. Corporation Information
11.12.2 BioLineRx, Ltd. Description and Business Overview
11.12.3 BioLineRx, Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 BioLineRx, Ltd. Products Offered
11.12.5 BioLineRx, Ltd. Related Developments
11.13 Boehringer Ingelheim GmbH
11.13.1 Boehringer Ingelheim GmbH Corporation Information
11.13.2 Boehringer Ingelheim GmbH Description and Business Overview
11.13.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Boehringer Ingelheim GmbH Products Offered
11.13.5 Boehringer Ingelheim GmbH Related Developments
11.14 Boston Biomedical, Inc.
11.14.1 Boston Biomedical, Inc. Corporation Information
11.14.2 Boston Biomedical, Inc. Description and Business Overview
11.14.3 Boston Biomedical, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Boston Biomedical, Inc. Products Offered
11.14.5 Boston Biomedical, Inc. Related Developments
11.15 Bristol-Myers Squibb Company
11.15.1 Bristol-Myers Squibb Company Corporation Information
11.15.2 Bristol-Myers Squibb Company Description and Business Overview
11.15.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Bristol-Myers Squibb Company Products Offered
11.15.5 Bristol-Myers Squibb Company Related Developments
11.16 Calithera Biosciences, Inc.
11.16.1 Calithera Biosciences, Inc. Corporation Information
11.16.2 Calithera Biosciences, Inc. Description and Business Overview
11.16.3 Calithera Biosciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Calithera Biosciences, Inc. Products Offered
11.16.5 Calithera Biosciences, Inc. Related Developments
11.17 Celgene Corporation
11.17.1 Celgene Corporation Corporation Information
11.17.2 Celgene Corporation Description and Business Overview
11.17.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Celgene Corporation Products Offered
11.17.5 Celgene Corporation Related Developments
11.18 Cornerstone Pharmaceuticals, Inc.
11.18.1 Cornerstone Pharmaceuticals, Inc. Corporation Information
11.18.2 Cornerstone Pharmaceuticals, Inc. Description and Business Overview
11.18.3 Cornerstone Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Cornerstone Pharmaceuticals, Inc. Products Offered
11.18.5 Cornerstone Pharmaceuticals, Inc. Related Developments
11.19 CTI BioPharma Corp.
11.19.1 CTI BioPharma Corp. Corporation Information
11.19.2 CTI BioPharma Corp. Description and Business Overview
11.19.3 CTI BioPharma Corp. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 CTI BioPharma Corp. Products Offered
11.19.5 CTI BioPharma Corp. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Region
12.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Regions 2021-2026
12.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast (2021-2026)
12.2.1 North America: Relapsed Acute Myeloid Leukemia Drug Sales Forecast (2021-2026)
12.2.2 North America: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast (2021-2026)
12.2.3 North America: Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Relapsed Acute Myeloid Leukemia Drug Sales Forecast (2021-2026)
12.3.2 Europe: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Relapsed Acute Myeloid Leukemia Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Relapsed Acute Myeloid Leukemia Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Relapsed Acute Myeloid Leukemia Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Relapsed Acute Myeloid Leukemia Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Relapsed Acute Myeloid Leukemia Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Relapsed Acute Myeloid Leukemia Drug Market Segments
Table 2. Ranking of Global Top Relapsed Acute Myeloid Leukemia Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of aNK Program
Table 5. Major Manufacturers of AT-9283
Table 6. Major Manufacturers of BI-836858
Table 7. Major Manufacturers of binimetinib
Table 8. Major Manufacturers of BL-8040
Table 9. Major Manufacturers of Others
Table 10. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Relapsed Acute Myeloid Leukemia Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Relapsed Acute Myeloid Leukemia Drug as of 2019)
Table 19. Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Price (2015-2020) (USD/Pcs)
Table 22. Relapsed Acute Myeloid Leukemia Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
Table 24. Date of International Manufacturers Enter into Relapsed Acute Myeloid Leukemia Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2015-2020)
Table 28. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2015-2020)
Table 30. Relapsed Acute Myeloid Leukemia Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2015-2020)
Table 33. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2015-2020)
Table 35. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Table 39. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Table 73. 4SC AG Corporation Information
Table 74. 4SC AG Description and Major Businesses
Table 75. 4SC AG Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. 4SC AG Product
Table 77. 4SC AG Recent Development
Table 78. AbbVie Inc. Corporation Information
Table 79. AbbVie Inc. Description and Major Businesses
Table 80. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. AbbVie Inc. Product
Table 82. AbbVie Inc. Recent Development
Table 83. Actinium Pharmaceuticals, Inc. Corporation Information
Table 84. Actinium Pharmaceuticals, Inc. Description and Major Businesses
Table 85. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Actinium Pharmaceuticals, Inc. Product
Table 87. Actinium Pharmaceuticals, Inc. Recent Development
Table 88. Agios Pharmaceuticals, Inc. Corporation Information
Table 89. Agios Pharmaceuticals, Inc. Description and Major Businesses
Table 90. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Agios Pharmaceuticals, Inc. Product
Table 92. Agios Pharmaceuticals, Inc. Recent Development
Table 93. Amgen Inc. Corporation Information
Table 94. Amgen Inc. Description and Major Businesses
Table 95. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Amgen Inc. Product
Table 97. Amgen Inc. Recent Development
Table 98. Arog Pharmaceuticals, Inc. Corporation Information
Table 99. Arog Pharmaceuticals, Inc. Description and Major Businesses
Table 100. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Arog Pharmaceuticals, Inc. Product
Table 102. Arog Pharmaceuticals, Inc. Recent Development
Table 103. Array BioPharma Inc. Corporation Information
Table 104. Array BioPharma Inc. Description and Major Businesses
Table 105. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Array BioPharma Inc. Product
Table 107. Array BioPharma Inc. Recent Development
Table 108. Astellas Pharma Inc. Corporation Information
Table 109. Astellas Pharma Inc. Description and Major Businesses
Table 110. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Astellas Pharma Inc. Product
Table 112. Astellas Pharma Inc. Recent Development
Table 113. Astex Pharmaceuticals, Inc. Corporation Information
Table 114. Astex Pharmaceuticals, Inc. Description and Major Businesses
Table 115. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Astex Pharmaceuticals, Inc. Product
Table 117. Astex Pharmaceuticals, Inc. Recent Development
Table 118. AstraZeneca Plc Corporation Information
Table 119. AstraZeneca Plc Description and Major Businesses
Table 120. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. AstraZeneca Plc Product
Table 122. AstraZeneca Plc Recent Development
Table 123. AVEO Pharmaceuticals, Inc. Corporation Information
Table 124. AVEO Pharmaceuticals, Inc. Description and Major Businesses
Table 125. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. AVEO Pharmaceuticals, Inc. Product
Table 127. AVEO Pharmaceuticals, Inc. Recent Development
Table 128. BioLineRx, Ltd. Corporation Information
Table 129. BioLineRx, Ltd. Description and Major Businesses
Table 130. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. BioLineRx, Ltd. Product
Table 132. BioLineRx, Ltd. Recent Development
Table 133. Boehringer Ingelheim GmbH Corporation Information
Table 134. Boehringer Ingelheim GmbH Description and Major Businesses
Table 135. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Boehringer Ingelheim GmbH Product
Table 137. Boehringer Ingelheim GmbH Recent Development
Table 138. Boston Biomedical, Inc. Corporation Information
Table 139. Boston Biomedical, Inc. Description and Major Businesses
Table 140. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. Boston Biomedical, Inc. Product
Table 142. Boston Biomedical, Inc. Recent Development
Table 143. Bristol-Myers Squibb Company Corporation Information
Table 144. Bristol-Myers Squibb Company Description and Major Businesses
Table 145. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. Bristol-Myers Squibb Company Product
Table 147. Bristol-Myers Squibb Company Recent Development
Table 148. Calithera Biosciences, Inc. Corporation Information
Table 149. Calithera Biosciences, Inc. Description and Major Businesses
Table 150. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. Calithera Biosciences, Inc. Product
Table 152. Calithera Biosciences, Inc. Recent Development
Table 153. Celgene Corporation Corporation Information
Table 154. Celgene Corporation Description and Major Businesses
Table 155. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. Celgene Corporation Product
Table 157. Celgene Corporation Recent Development
Table 158. Cornerstone Pharmaceuticals, Inc. Corporation Information
Table 159. Cornerstone Pharmaceuticals, Inc. Description and Major Businesses
Table 160. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 161. Cornerstone Pharmaceuticals, Inc. Product
Table 162. Cornerstone Pharmaceuticals, Inc. Recent Development
Table 163. CTI BioPharma Corp. Corporation Information
Table 164. CTI BioPharma Corp. Description and Major Businesses
Table 165. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 166. CTI BioPharma Corp. Product
Table 167. CTI BioPharma Corp. Recent Development
Table 168. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 169. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Regions (2021-2026)
Table 170. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 171. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 172. North America: Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 173. North America: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 174. Europe: Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 175. Europe: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 176. Asia Pacific: Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 177. Asia Pacific: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 178. Latin America: Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 179. Latin America: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 180. Middle East and Africa: Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 181. Middle East and Africa: Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 182. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 183. Key Challenges
Table 184. Market Risks
Table 185. Main Points Interviewed from Key Relapsed Acute Myeloid Leukemia Drug Players
Table 186. Relapsed Acute Myeloid Leukemia Drug Customers List
Table 187. Relapsed Acute Myeloid Leukemia Drug Distributors List
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Product Picture
Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type in 2020 & 2026
Figure 3. aNK Program Product Picture
Figure 4. AT-9283 Product Picture
Figure 5. BI-836858 Product Picture
Figure 6. binimetinib Product Picture
Figure 7. BL-8040 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Relapsed Acute Myeloid Leukemia Drug Report Years Considered
Figure 14. Global Relapsed Acute Myeloid Leukemia Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2019
Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in 2019
Figure 21. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2019
Figure 23. Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type in 2019
Figure 26. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type in 2019
Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Price Range (2015-2020)
Figure 29. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application in 2019
Figure 31. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application in 2019
Figure 33. North America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2019
Figure 36. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2019
Figure 42. North America Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2019
Figure 43. Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2019
Figure 46. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2019
Figure 47. Germany Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2019
Figure 58. Europe Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2019
Figure 59. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in 2019
Figure 63. China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2019
Figure 86. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2019
Figure 87. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2019
Figure 90. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2019
Figure 98. Latin America Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2019
Figure 111. North America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
急性骨髄性白血病の世界市場（～2026年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …- 急性骨髄性白血病治療薬の世界市場（～2026年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…
- 急性リンパ芽球性白血病薬の世界市場（～2026年） Market Analysis and Insights: Global Acute Lymphoblastic Leukemia Drug Market The global Acute Lymphoblastic Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Acute Lymphoblastic Leukemia Drug Scope and Mar…
- 白血病の世界市場（～2026年） Leukemia is a group ofcancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. High incidence rate of blood cancers and rise in incidence of leukaemia across the globe will drive the leukemia market. Market Analysis and Insights: Global Leukemia Cancer …
- 白血病治療薬の世界市場（～2026年） Leukemia Treatment Drugs is used to cure Leukemia. Increasing geriatric population base and high unmet needs regarding early diagnosis and treatment of leukemia are the key factors driving the leukemia therapeutics market. Market Analysis and Insights: Global Leukemia Treatment Drugs Market The glob…